Trademark Overview
On Wednesday, April 16, 2025, a trademark application was filed for LADRUPI with the United States Patent and Trademark Office. The USPTO has given the LADRUPI trademark a serial number of 99139579. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Wednesday, April 16, 2025. This trademark is owned by Glaxo Group Limited. The LADRUPI trademark is filed in the Pharmaceutical Products category with the following description:
Vaccines; Anti-infectives; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of infectious disease